These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1006 related items for PubMed ID: 18497466

  • 21. Pulse pressure monitoring of open antihypertensive therapy.
    Safar ME, Vaisse B, Blacher J, Rudnichi A, Mourad JJ.
    Am J Hypertens; 2004 Dec; 17(12 Pt 1):1088-94. PubMed ID: 15607613
    [Abstract] [Full Text] [Related]

  • 22. Impact of lower achieved blood pressure on outcomes in hypertensive patients.
    Okin PM, Hille DA, Kjeldsen SE, Dahlöf B, Devereux RB.
    J Hypertens; 2012 Apr; 30(4):802-10; discussion 810. PubMed ID: 22343536
    [Abstract] [Full Text] [Related]

  • 23. Impact of blood pressure variability on cardiovascular events in elderly patients with hypertension.
    Eto M, Toba K, Akishita M, Kozaki K, Watanabe T, Kim S, Hashimoto M, Ako J, Iijima K, Sudoh N, Yoshizumi M, Ouchi Y.
    Hypertens Res; 2005 Jan; 28(1):1-7. PubMed ID: 15969248
    [Abstract] [Full Text] [Related]

  • 24. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
    Egan B, Gleim G, Panish J.
    Curr Med Res Opin; 2004 Dec; 20(12):1909-17. PubMed ID: 15701209
    [Abstract] [Full Text] [Related]

  • 25. Current status of antihypertensive prescription and associated blood pressure control in Japan.
    Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M, Umemura S.
    Hypertens Res; 2006 Mar; 29(3):143-51. PubMed ID: 16755149
    [Abstract] [Full Text] [Related]

  • 26. Office blood pressure variability as a predictor of acute myocardial infarction in elderly patients receiving antihypertensive therapy.
    Hata Y, Muratani H, Kimura Y, Fukiyama K, Kawano Y, Ashida T, Yokouchi M, Imai Y, Ozawa T, Fujii J, Omae T.
    J Hum Hypertens; 2002 Feb; 16(2):141-6. PubMed ID: 11850772
    [Abstract] [Full Text] [Related]

  • 27. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
    McInnes G, Burke TA, Carides G.
    J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874
    [Abstract] [Full Text] [Related]

  • 28. Isolated systolic hypertension as a major risk factor for stroke and myocardial infarction and an unexploited source of cardiovascular prevention: a prospective population-based study.
    Nielsen WB, Vestbo J, Jensen GB.
    J Hum Hypertens; 1995 Mar; 9(3):175-80. PubMed ID: 7783098
    [Abstract] [Full Text] [Related]

  • 29. Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders.
    Ellis D, Moritz ML, Vats A, Janosky JE.
    Am J Hypertens; 2004 Oct; 17(10):928-35. PubMed ID: 15485756
    [Abstract] [Full Text] [Related]

  • 30. Improvement of blood pressure control in hypertensive patients with renal diseases.
    Ohta Y, Tsuruya K, Fujii K, Tokumoto M, Kanai H, Matsumura K, Tsuchihashi T, Hirakata H, Iida M.
    Hypertens Res; 2007 Apr; 30(4):295-300. PubMed ID: 17541207
    [Abstract] [Full Text] [Related]

  • 31. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.
    Dolan E, Stanton AV, Thom S, Caulfield M, Atkins N, McInnes G, Collier D, Dicker P, O'Brien E, ASCOT Investigators.
    J Hypertens; 2009 Apr; 27(4):876-85. PubMed ID: 19516185
    [Abstract] [Full Text] [Related]

  • 32. Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives.
    Cruickshank JM, Pennert K, Sörman AE, Thorp JM, Zacharias FM, Zacharias FJ.
    J Hypertens; 1987 Aug; 5(4):489-98. PubMed ID: 3668249
    [Abstract] [Full Text] [Related]

  • 33. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
    Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z, Edelman JM, Shahinfar S.
    Am J Cardiol; 2005 Dec 01; 96(11):1530-6. PubMed ID: 16310435
    [Abstract] [Full Text] [Related]

  • 34. [Target values in hypertension treatment. Will they apply in older patients with hypertension, diabetics and in patients with IHD?].
    Widimský J.
    Vnitr Lek; 2009 Sep 01; 55(9):833-40. PubMed ID: 19785385
    [Abstract] [Full Text] [Related]

  • 35. Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors.
    Aksnes TA, Reims HM, Guptha S, Moan A, Os I, Kjeldsen SE.
    J Hum Hypertens; 2006 Nov 01; 20(11):860-6. PubMed ID: 16988754
    [Abstract] [Full Text] [Related]

  • 36. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
    Bangalore S, Messerli FH, Franklin SS, Mancia G, Champion A, Pepine CJ.
    Eur Heart J; 2009 Jun 01; 30(11):1395-401. PubMed ID: 19351690
    [Abstract] [Full Text] [Related]

  • 37. Improvement of blood pressure control in a hypertension clinic in Japan: a 15-year follow-up study.
    Ohta Y, Matsumura K, Tsuchihashi T, Ohtsubo T, Arima H, Miwa Y, Goto K, Ohya Y, Fujii K, Uezono K, Abe I, Iida M.
    Clin Exp Hypertens; 2009 Oct 01; 31(7):553-9. PubMed ID: 19886853
    [Abstract] [Full Text] [Related]

  • 38. Progress report on The Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP) study: status at February 2004.
    Hosohata K, Saito S, Asayama K, Ohkubo T, Kikuya M, Metoki H, Obara T, Kato T, Hashimoto J, Totsune K, Miura Y, Imai Y, HOMED-BP Study Group.
    Clin Exp Hypertens; 2007 Jan 01; 29(1):69-81. PubMed ID: 17190733
    [Abstract] [Full Text] [Related]

  • 39. Improvement of blood pressure control in a hypertension clinic: a 10-year follow-up study.
    Ohta Y, Tsuchihashi T, Fujii K, Matsumura K, Ohya Y, Uezono K, Abe I, Iida M.
    J Hum Hypertens; 2004 Apr 01; 18(4):273-8. PubMed ID: 15037877
    [Abstract] [Full Text] [Related]

  • 40. Reverse white-coat effect as an independent risk for microalbuminuria in treated hypertensive patients.
    Kato T, Horio T, Tomiyama M, Kamide K, Nakamura S, Yoshihara F, Nakata H, Nakahama H, Kawano Y.
    Nephrol Dial Transplant; 2007 Mar 01; 22(3):911-6. PubMed ID: 17142262
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 51.